Dimpled-chin Botox: mentalis movement, off-label use, and the right endpoint
Botulinum toxin in the mentalis can be discussed for contraction-related chin dimpling, but this is not a BOTOX Cosmetic-labeled chin indication. It addresses a movement pattern, not a small or recessed chin.
Botulinum toxin in the mentalis is an off-label cosmetic approach to chin dimpling that is most apparent when that muscle contracts. It is a different decision from adding chin projection or changing bone structure. BOTOX Cosmetic’s current U.S. label lists other facial and neck indications, not a chin indication; a small controlled study of chin rhytids supplies limited site-specific evidence, not an FDA approval or a predictable individual outcome.123
Is the concern movement, surface, or projection?
The mentalis helps move the lower lip and chin skin. In some expressions, the chin surface bunches into a dimpled or “cobblestone” appearance. A photograph at rest and another with the relevant expression can make that distinction easier to discuss. The consultation should avoid translating every chin complaint into a muscle problem.
| What is noticed | Why it changes the question | What not to infer |
|---|---|---|
| Dimpling mainly with a facial movement | A mentalis-driven component may be considered | That the whole chin contour will change |
| A recessed chin in profile | Projection and structural options are a separate job | That toxin adds volume or bone projection |
| A mark or crease present at rest | Skin texture and prior changes matter | That a movement treatment erases a static line |
| Difficulty with lip seal or expression | Function belongs in the initial assessment | That an aesthetic injection is automatically suitable |
The chin implant-versus-filler article addresses projection, not mentalis contraction. Keeping those topics separate helps a practice propose a measurable endpoint—less visible movement-related bunching—rather than a vague promise of a “better chin.”
What off-label means here
The absence of a mentalis indication in the BOTOX Cosmetic label does not, by itself, make a clinician’s use unlawful. It does mean FDA did not approve that specific cosmetic claim in the product labeling. The exact product name matters: “Botox” is often used conversationally for multiple botulinum-toxin products whose units and approvals are not interchangeable. Ask the practice which product it plans to use and whether the chin use is off-label.13
The label’s boxed warning and adverse-effect language still matter even when the intended cosmetic endpoint is small. The lower face is functionally busy: a consultation should cover eating, speaking, expression, existing asymmetry and a plan for an unwanted change. None of that requires a reader to decide an injection pattern or dose at home. For the general regulatory distinction, see off-label cosmetic use.1
Read the evidence at the size it was studied
The published placebo-controlled chin-rhytid study is useful because it actually evaluated the chin instead of extrapolating from forehead trials. It is also limited: a small study, older product-era methods, and a particular cosmetic outcome do not prove that every dimple is mentalis-driven or that a chosen treatment will have a uniform effect. The study does not address chin recession or support a promise about how long an individual’s appearance will change.2
An informative consultation identifies the expression being assessed, records the baseline, and names a functional check as well as the aesthetic goal. That approach is more useful than a close-up social-media result with no movement, product, timing or adverse-event context.
A lower-face plan needs a functional baseline
The mentalis participates in lower-lip movement, so a chin-texture plan should not be assessed only by whether the chin looks smoother in a still photograph. Ask the clinician to observe ordinary speech, lip closure, smiling and the expression that produces dimpling. A baseline record helps distinguish a pre-existing asymmetry from a treatment-related change later. It also makes the intended result more precise: less bunching during a named movement, not a wholesale change in lower-face shape.
If the complaint is a shadow under the lower lip, it may not be the same as surface dimpling. If it is a crease visible at rest, the role of repeated movement may differ from a mark that disappears completely when relaxed. A provider may discuss several explanations, but each should be connected to a different endpoint. A request for “chin Botox” should not become a default injection simply because that phrase is familiar online.
The original placebo-controlled trial examined chin rhytids, not every lower-face concern. Ask what the study measured, whether the proposed product and target resemble the study, and how its limits apply. A small trial can show that a question has been studied without establishing a broad standard of care or a guaranteed number of weeks of benefit. If a clinic quotes a dramatic improvement rate, ask for the exact source and whether the statistic belongs to the mentalis trial rather than a forehead-label study.2
Finally, distinguish a service quote from a consent discussion. A quote might name units or an area, but it cannot convey the patient’s baseline function, the possibility of altered lip movement, or the plan if the aesthetic goal is missed. Those need a real conversation with the treating clinician. The Botox unit guide explains why a unit count alone is not a comparative outcome measure.
Use Treomark’s Botox provider page to arrange an assessment, then ask for the exact product and a documented goal. The best answer may be that another structure, rather than mentalis movement, is the main issue.
Sources
- National Library of Medicine DailyMed. BOTOX Cosmetic prescribing information. Current labeled cosmetic sites and boxed warning; the mentalis/chin is not a listed aesthetic indication. Accessed .
- Journal of Drugs in Dermatology. A double-blinded, placebo-controlled study of Botox for chin rhytids. Small original chin-rhytid study; evidence for a selected movement/skin endpoint, not chin projection or a broad approval. Accessed .
- U.S. Food and Drug Administration. Understanding unapproved use of approved drugs. Explains that lawful clinician off-label use is distinct from an FDA-approved indication. Accessed .